Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1406.75% is 100% above its 5-year average of -1291614.80%, near the high end of its 5-year range (-10096476.76%–-843.21%).
12.55% above its 12-month average of -1608.57%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -2373.92%.
EBITDA MARGIN
-1406.75%
EBITDA MARGIN AVG TTM
-1608.57%
EBITDA MARGIN AVG 3Y
-32964.17%
EBITDA MARGIN AVG 5Y
-1291614.80%
EBITDA MARGIN AVG 10Y
-26344.87%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+12.55%
CURRENT VS 3Y AVG
+95.73%
CURRENT VS 5Y AVG
+99.89%
CURRENT VS 10Y AVG
+94.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Crescent Biopharma, Inc.
Market Cap
$523.36M
EBITDA Margin
-1406.75%
TTM Avg
-1608.57%
3Y Avg
-32964.17%
5Y Avg
-1291614.80%
Market Cap
$515.36M
EBITDA Margin
-230187.80%
TTM Avg
-372428.90%
3Y Avg
-255754.79%
5Y Avg
-154022.75%
Market Cap
$533.42M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$511.20M
EBITDA Margin
-35.08%
TTM Avg
-77.94%
3Y Avg
-77.08%
5Y Avg
-62.83%
Market Cap
$549.58M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
Market Cap
$495.64M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $523.36M | -1406.75% | -1608.57% | -32964.17% | -1291614.80% |
| Immix Biopharma, Inc. (IMMX)vs › | $522.26M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
| Delcath Systems, Inc. (DCTH)vs › | $533.42M | 1.18% | -15.78% | -775.36% | -845.24% |
| Monopar Therapeutics Inc. (MNPR)vs › | $511.25M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $511.20M | -35.08% | -77.94% | -77.08% | -62.83% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.32M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | -970.11% | -861.99% | -583.02% | -735.09% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $495.64M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $551.88M | -27.54% | -4.08% | -49.61% | -102.69% |
Gross Margin
100.0%
EBITDA Margin
-1406.8%
Operating Margin
-1407.5%
Net Margin
-1371.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -2373.92% |
| 2025-12-31 | -843.21% |
| 2023-12-31 | -95675.37% |
| 2022-06-30 | -17731.18% |
| 2021-12-31 | -98520.45% |
| 2021-09-30 | -19950.97% |
| 2021-06-30 | -10096476.76% |
| 2021-03-31 | -1346.53% |
| 2020-12-31 | -9512.99% |
| 2020-09-30 | -1366.08% |
| 2020-03-31 | -89.33% |
| 2016-09-30 | -42383.50% |
| 2015-12-31 | -24985.04% |
| 2015-06-30 | 52.07% |
| 2014-06-30 | 53.92% |
| 2013-12-31 | -4943.18% |
| 2013-09-30 | -6976.47% |
| 2013-06-30 | -6290.77% |
| 2013-03-31 | 12.89% |
| 2012-12-31 | 17.25% |
| 2012-09-30 | 22.24% |
